Owen Hughes (L) and Patrick Baeuerle, Cullinan (Cullinan Oncology)

Fu­eled with a fresh cash in­jec­tion, Cul­li­nan ex­pands its pipeline with a bid to de­vel­op a new com­bi­na­tion drug for the check­point class

Fresh off of a $98.5 mil­lion raise, Patrick Baeuer­le’s team at Cul­li­nan On­col­o­gy has a new sub­sidiary they’re bring­ing in­to the pack.

This one, their 8th drug de­vel­op­ment op­er­a­tion, is called Cul­li­nan MI­CA, named af­ter a tar­get they be­lieve has broad ap­plic­a­bil­i­ty against mul­ti­ple can­cers, quite like­ly in a po­ten­tial com­bi­na­tion with the check­points that have been chang­ing up the prac­tice of med­i­cine for can­cer pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.